ROYALTY PHARMA PLC
RPRXLoading price...
Overview
Previous Close57.48
Open59.53
Ask62.19
Bid53.62
Day's Range57.41 - 59.63
52 Week Range34.08 - 60.44
PE Ratio(TTM)30.24
Market Cap33.25B
Volume3.52M
Avg. Volume3.63M
12 Months Earnings770.95M
12 Months Revenue2.38B
Performance
ABSCAGR
| YTD | 1 Month | 3 Months | 1 Year | 2 Years | 5 Years | 10 Years | |
|---|---|---|---|---|---|---|---|
| No results to display | |||||||
Profit/Loss
| PARTICULARS | TTM | 2025 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|---|
| Operating Revenue | 2.38B | 2.38B | 2.31B | 2.26B | 2.35B | 2.24B |
| Operating Expenses | 818.67M | 818.67M | 464.68M | 971.13M | 862.40M | 1.31B |
| Profit after Tax (Net Income) | 770.95M | 770.95M | 1.02B | 858.98M | 1.13B | 42.83M |
Company Profile
Sector: Healthcare
Industry: Biotechnology
HQ Location: New York, United States
Website: https://www.royaltypharma.com
Founder, Chairman of the Board & CEO: Mr. Pablo Legorreta
Employees: 100
About Company:
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.